Company: Incyte Corporation
Bloomberg ticker: INCY US
Market cap: US$16,227m
Background: Incyte Corporation, a U.S.-based biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics. It operates globally, specializing in oncology and inflammation. Its key products include Jakafi (ruxolitinib), a treatment for certain blood cancers, and Opzelura, a cream for dermatological conditions.
World Class Benchmarking of Incyte Corp
(Click on image to enlarge)
- Profitable Growth rank of 1 was up compared to the prior period’s 10th rank
- This is World Class performance compared to 350 large Health Care companies worldwide
- Profitability rank of 2 was worse than its Growth rank of 1
- Profitability rank of 2 was up compared to the prior period’s 9th rank
- This is World Class performance compared to peers
- Growth rank of 1 was up compared to the prior period’s 10th rank
- This is World Class performance compared to peers
More By This Author:
Stock Analysis: Maple Leaf Foods
Stock Analysis: Dharma Satya Nusantara
Stock Analysis: LG Electronics
Comments
Log in or sign up to join the conversation.